诚达药业
(301201)
| 流通市值：21.18亿 | | | 总市值：37.58亿 |
| 流通股本：8719.38万 | | | 总股本：1.55亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 243,768,662.64 | 164,012,180.77 | 100,889,692.8 | 414,301,764.07 |
| 营业收入 | 243,768,662.64 | 164,012,180.77 | 100,889,692.8 | 414,301,764.07 |
| 二、营业总成本 | 235,403,173.38 | 164,252,771.69 | 88,945,893.49 | 351,493,181.66 |
| 营业成本 | 137,620,876.91 | 99,639,206.77 | 59,725,938.9 | 236,622,826.36 |
| 税金及附加 | 2,274,425.31 | 2,168,239.69 | 423,117.98 | 3,572,634.62 |
| 销售费用 | 3,337,089.69 | 2,176,166.47 | 936,908.25 | 3,195,121.01 |
| 管理费用 | 65,621,516.21 | 44,124,262.7 | 18,966,702.67 | 88,358,306.8 |
| 研发费用 | 29,780,273.67 | 19,112,923.27 | 9,782,578.34 | 27,464,739.25 |
| 财务费用 | -3,231,008.41 | -2,968,027.21 | -889,352.65 | -7,720,446.38 |
| 其中:利息费用 | - | 12,364.42 | 10,064.42 | - |
| 其中:利息收入 | 1,668,431 | 1,212,490.8 | 776,605 | 6,367,723.74 |
| 加:公允价值变动收益 | 4,972,835.53 | 3,664,720.51 | - | - |
| 加:投资收益 | 23,819,115.33 | 18,833,376.8 | 9,336,423.89 | 41,823,851.31 |
| 资产处置收益 | 204,739.69 | 129,452.19 | 91,874.66 | 3,266.23 |
| 资产减值损失(新) | -3,628,172.55 | -1,117,463.06 | -818,662.77 | 3,655,159.97 |
| 信用减值损失(新) | 5,975,640.27 | 4,445,643.97 | 1,029,013.38 | -6,025,695.06 |
| 其他收益 | 4,994,849.34 | 1,873,074.6 | 1,401,350.23 | 5,533,962.76 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 44,704,496.87 | 27,588,214.09 | 22,983,798.7 | 107,799,127.62 |
| 加:营业外收入 | 11,713.64 | 6,163.74 | 2,385.74 | 99,432.11 |
| 减:营业外支出 | 2,279,295.31 | 1,337,869.59 | 948,949.92 | 3,648,588.51 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 42,436,915.2 | 26,256,508.24 | 22,037,234.52 | 104,249,971.22 |
| 减:所得税费用 | 1,900,652.89 | 1,048,688.45 | 3,310,948.33 | 13,147,943.32 |
| 六、净利润 | 40,536,262.31 | 25,207,819.79 | 18,726,286.19 | 91,102,027.9 |
| 持续经营净利润 | 40,536,262.31 | 25,207,819.79 | 18,726,286.19 | 91,102,027.9 |
| 归属于母公司股东的净利润 | 40,392,784.63 | 25,174,792.07 | 18,644,506 | 90,980,328.72 |
| 少数股东损益 | 143,477.68 | 33,027.72 | 81,780.19 | 121,699.18 |
| (一)基本每股收益 | 0.27 | 0.17 | 0.12 | 0.59 |
| (二)稀释每股收益 | 0.27 | 0.17 | 0.12 | 0.59 |
| 九、综合收益总额 | 40,536,262.31 | 25,207,819.79 | 18,726,286.19 | 91,102,027.9 |
| 归属于母公司股东的综合收益总额 | 40,392,784.63 | 25,174,792.07 | 18,644,506 | 90,980,328.72 |
| 归属于少数股东的综合收益总额 | 143,477.68 | 33,027.72 | 81,780.19 | 121,699.18 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-22 | 2024-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |